Thermo Fisher Sells Microbiology Business

Astorg to Acquire Microbiology Division

Thermo Fisher Scientific has signed an agreement to sell its microbiology business to private equity firm Astorg in a transaction valued at approximately $1.075 billion. The deal includes cash consideration along with a $50 million seller note and is expected to strengthen Thermo Fisher’s focus on strategic growth areas within its life sciences and diagnostics portfolio.

Expanding Independent Growth Opportunities

The microbiology business provides antimicrobial susceptibility testing and culture media solutions used across clinical diagnostics, pharmaceutical manufacturing and food safety testing environments. Following the acquisition, the business will operate as an independent platform supported by Astorg’s healthcare investment and operational expertise.

Supporting Laboratory and Diagnostic Markets

The divested business generated approximately $645 million in revenue and includes global manufacturing and R&D operations supporting microbiology testing workflows. The transaction is intended to help accelerate future expansion of microbiology solutions while maintaining support for laboratory, pharmaceutical and food-safety customers worldwide.

Key Highlights

• Thermo Fisher to sell microbiology business to Astorg

• Transaction valued at approximately $1.075 billion

• Includes $50 million seller note

• Focus on antimicrobial testing and culture media

• Global microbiology manufacturing and R&D operations

• Expansion of independent healthcare platform

Applications

• Clinical microbiology laboratories

• Pharmaceutical quality testing

• Food safety analysis

• Antimicrobial susceptibility testing

• Diagnostic laboratory workflows

• Biopharmaceutical research environments

Strengthening Future Diagnostic Growth

As healthcare and laboratory markets continue evolving, companies are increasingly focusing on specialized business strategies and operational expansion. The agreement between Thermo Fisher Scientific and Astorg supports continued development of microbiology testing technologies while enabling broader investment opportunities across global diagnostic and laboratory markets.